Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors

被引：77

作者：

Casadei, Chiara ^{[1
]}

Dizman, Nazli ^{[2
]}

Schepisi, Giuseppe ^{[1
]}

Cursano, Maria Concetta ^{[3
]}

Basso, Umberto ^{[4
]}

Santini, Daniele ^{[3
]}

Pal, Sumanta K. ^{[2
]}

De Giorgi, Ugo ^{[1
]}

机构：

[1] IRCCS, Ist Sci Romagnolo Studio & Cura Tumori IRST, Dept Med Oncol, Via Maroncelli 40, I-47014 Meldola, Italy

[2] City Hope Comprehens Canc Ctr, Dept Med Oncol & Therapeut Res, Duarte, CA USA

[3] Univ Rome, Dept Med Oncol, Campus Biomed, Rome, Italy

[4] IRCCS, IOV, Med Oncol Unit, Padua, Italy

来源：

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | 2019年 / 11卷

关键词：

erdafitinib; FGFR inhibitors; infigratinib; rogaratinib; urothelial cancer; vofatamab; METASTATIC UROTHELIAL CARCINOMA; PHASE-II TRIAL; TUMOR MICROENVIRONMENT; SELECTIVE INHIBITOR; CLINICAL ACTIVITY; DOSE-ESCALATION; DOWN-REGULATION; GENE FUSIONS; OPEN-LABEL; GROWTH;

D O I：

10.1177/1758835919890285

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Inhibitors of fibroblast growth factor receptor (FGFR) represent an outstanding treatment approach for selected patients with urothelial cancer (UC). These agents are changing the clinical approach to a subgroup of UC, the luminal-papillary subtype, characterized by FGFR mutations, fusions, or amplification. In this review, we provide an overview of the results of recent clinical trials on FGFR tyrosine kinase inhibitors (TKIs) currently in clinical development for the treatment of UC: erdafitinib, rogaratinib, infigratinib, and the monoclonal antibody vofatamab. The Food and Drug Administration recently granted accelerated approval to erdafitinib for patients with advanced UC with alterations of FGFR2 or FGFR3 after progression on platinum-based chemotherapy. We also look at future therapeutic options of combination regimens with immune-checkpoint inhibitors as strategies for improving the antitumor effects of this class of drug, and for preventing or delaying the development of resistance.

引用

页数：14

共 97 条

[1] FGF5 as an oncogenic factor in human glioblastoma multiforme: autocrine and paracrine activities [J].

Allerstorfer, S. ;

Sonvilla, G. ;

Fischer, H. ;

Spiegl-Kreinecker, S. ;

Gauglhofer, C. ;

Setinek, U. ;

Czech, T. ;

Marosi, C. ;

Buchroithner, J. ;

Pichler, J. ;

Silye, R. ;

Mohr, T. ;

Holzmann, K. ;

Grasl-Kraupp, B. ;

Marian, B. ;

Grusch, M. ;

Fischer, J. ;

Micksche, M. ;

Berger, W. .

ONCOGENE, 2008, 27 (30) :4180-4190

[2]

Andre F, 2017, J CLIN ONCOL S, V29, P289

[3]

Angevin E, 2009, J CLIN ONCOL, V27

[4]

[Anonymous], 2016, CHINESE J TISSUE ENG

[5]

[Anonymous], 2019, J CLIN ONCOL S

[6] Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study [J].

Apolo, Andrea B. ;

Infante, Jeffrey R. ;

Balmanoukian, Ani ;

Patel, Manish R. ;

Wang, Ding ;

Kelly, Karen ;

Mega, Anthony E. ;

Britten, Carolyn D. ;

Ravaud, Alain ;

Mita, Alain C. ;

Safran, Howard ;

Stinchcombe, Thomas E. ;

Srdanov, Marko ;

Gelb, Arnold B. ;

Schlichting, Michael ;

Chin, Kevin ;

Gulley, James L. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (19) :2117-+

[7] IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun). [J].

Atkins, Michael B. ;

McDermott, David F. ;

Powles, Thomas ;

Motzer, Robert J. ;

Rini, Brian I. ;

Fong, Lawrence ;

Joseph, Richard Wayne ;

Pal, Sumanta K. ;

Sznol, Mario ;

Hainsworth, John D. ;

Stadler, Walter Michael ;

Hutson, Thomas E. ;

Ravaud, Alain ;

Bracarda, Sergio ;

Suarez, Cristina ;

Choueiri, Toni K. ;

Qiu, Jiaheng ;

Huseni, Mahrukh A. ;

Schiff, Christina ;

Escudier, Bernard J. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

[8] First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study [J].

Balar, Arjun V. ;

Castellano, Daniel ;

O'Donnell, Peter H. ;

Grivas, Petros ;

Vuky, Jacqueline ;

Powles, Thomas ;

Plimack, Elizabeth R. ;

Hahn, Noah M. ;

de Wit, Ronald ;

Pang, Lei ;

Savage, Mary J. ;

Perini, Rodolfo F. ;

Keefe, Stephen M. ;

Bajorin, Dean ;

Bellmunt, Joaquim .

LANCET ONCOLOGY, 2017, 18 (11) :1483-1492

[9] Next-generation sequencing (NGS) of cell-free circulating tumor DNA and tumor tissue in patients with advanced urothelial cancer: a pilot assessment of concordance [J].

Barata, P. C. ;

Koshkin, V. S. ;

Funchain, P. ;

Sohal, D. ;

Pritchard, A. ;

Klek, S. ;

Adamowicz, T. ;

Gopalakrishnan, D. ;

Garcia, J. ;

Rini, B. ;

Grivas, P. .

ANNALS OF ONCOLOGY, 2017, 28 (10) :2458-2463

[10] The FGF family: biology, pathophysiology and therapy [J].

Beenken, Andrew ;

Mohammadi, Moosa .

NATURE REVIEWS DRUG DISCOVERY, 2009, 8 (03) :235-253

← 1 2 3 4 5 6 7 8 9 10 →